Chaicharn Deerochanawong
Biographic Data
| ID | 9005747 |
|---|---|
| NAME | Chaicharn Deerochanawong |
| GIVEN NAMES | Chaicharn |
| FAMILY NAME | Deerochanawong |
| SIGNATURE | DEEROCHANAWONG C |
| AFFILIATIONS | Ministry of Public Health |
| ORCID | 0000-0001-9666-7050 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2013 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand
Objective: This study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer's perspective. Methods: The budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar trea…
Diabetes management in Thailand
Management of diabetes represents an enormous challenge for health systems at every level of development. The latter are tested for their ability to continuously deliver high quality care to patients from the day they are diagnosed throughout their life. In this study, we review the status of diabetes management in Thailand and try to identify the key challenges the country needs to address to reduce the current (and future) medical and economic …
No prominent works on this page.
Diabetes management in Thailand
Management of diabetes represents an enormous challenge for health systems at every level of development. The latter are tested for their ability to continuously deliver high quality care to patients from the day they are diagnosed throughout their life. In this study, we review the status of diabetes management in Thailand and try to identify the key challenges the country needs to address to reduce the current (and future) medical and economic …
Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand
Objective: This study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer's perspective. Methods: The budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar trea…
Diabetes Management and Education (2 works) · Diabetes mellitus (2 works) · Medicine (2 works) · Type 2 diabetes (2 works) · Chronic Disease Management Strategies (1 work) · Diabetes management (1 work) · Diabetes, Cardiovascular Risks, and Lipoproteins (1 work) · Disease (1 work) · Disease burden (1 work) · Disease management (1 work)